Tomás Zambrano1, Mario Hiroyuki Hirata2, Álvaro Cerda1, Egidio L Dorea3, Gelba A Pinto3, Maria C Gusukuma3, Marcelo C Bertolami4, Luis A Salazar5, Rosario Dominguez Crespo Hirata2. 1. School of Pharmaceutical Sciences, University of Sao Paulo São Paulo, Brazil ; Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus (BIOREN), Universidad de La Frontera Temuco, Chile. 2. School of Pharmaceutical Sciences, University of Sao Paulo São Paulo, Brazil. 3. University Hospital, University of Sao Paulo São Paulo, Brazil. 4. Institute Dante Pazzanese of Cardiology Sao Paulo, Brazil. 5. Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus (BIOREN), Universidad de La Frontera Temuco, Chile.
Abstract
BACKGROUND: Hypercholesterolemia is a complex trait, resulting from a genetic interaction with lifestyle habits. Polymorphisms are a major source of genetic heterogeneity, and variations in 2 key cholesterol homeostasis genes; low-density lipoprotein receptor (LDLR) and proprotein convertase subtilisin/kexin type-9 (PCSK9), lead to dyslipidemia. So, we investigated the relation of 2 variants located in the 3'-UTR (3'-untranslated region) of LDLR (rs14158, G>A) and PCSK9 (rs17111557, C>T) with lipid profile and atorvastatin response. METHODS: SNP influence on lipid profile was assessed in hypercholesterolemic patients (HC; n = 89) using atorvastatin (10 mg/day/4 weeks) and in normolipidemic subjects (NL; n = 171). Genotyping was completed through real-time PCR using TaqMan assays. RESULTS: rs14158 G allele was higher in HC than in NL group (P = 0.043). NL subjects carrying the T allele of the PCSK9 variant had lower high-density lipoprotein cholesterol (HDL-c) than C allele carriers (P = 0.009). There was no association between LDLR and PCSK9 SNPs and atorvastatin response. Additionally, the PCSK9 variant creates a microRNA interaction site, which could implicate an epigenetic mechanism in PCSK9-dependent HDL-C regulation. CONCLUSIONS: The rs14158 SNP contributes to hypercholesterolemia. Also, a putative microRNA regulation may influence HDL-C variability observed in rs17111557 carriers. Cholesterol-lowering response to atorvastatin is not influenced by LDLR and PCSK9 variants.
BACKGROUND:Hypercholesterolemia is a complex trait, resulting from a genetic interaction with lifestyle habits. Polymorphisms are a major source of genetic heterogeneity, and variations in 2 key cholesterol homeostasis genes; low-density lipoprotein receptor (LDLR) and proprotein convertase subtilisin/kexin type-9 (PCSK9), lead to dyslipidemia. So, we investigated the relation of 2 variants located in the 3'-UTR (3'-untranslated region) of LDLR (rs14158, G>A) and PCSK9 (rs17111557, C>T) with lipid profile and atorvastatin response. METHODS: SNP influence on lipid profile was assessed in hypercholesterolemicpatients (HC; n = 89) using atorvastatin (10 mg/day/4 weeks) and in normolipidemic subjects (NL; n = 171). Genotyping was completed through real-time PCR using TaqMan assays. RESULTS:rs14158 G allele was higher in HC than in NL group (P = 0.043). NL subjects carrying the T allele of the PCSK9 variant had lower high-density lipoprotein cholesterol (HDL-c) than C allele carriers (P = 0.009). There was no association between LDLR and PCSK9 SNPs and atorvastatin response. Additionally, the PCSK9 variant creates a microRNA interaction site, which could implicate an epigenetic mechanism in PCSK9-dependent HDL-C regulation. CONCLUSIONS: The rs14158 SNP contributes to hypercholesterolemia. Also, a putative microRNA regulation may influence HDL-C variability observed in rs17111557 carriers. Cholesterol-lowering response to atorvastatin is not influenced by LDLR and PCSK9 variants.
Authors: J Alves-Silva; M da Silva Santos; P E Guimarães; A C Ferreira; H J Bandelt; S D Pena; V F Prado Journal: Am J Hum Genet Date: 2000-06-28 Impact factor: 11.025
Authors: Mark J Graham; Kristina M Lemonidis; Charles P Whipple; Amuthakannan Subramaniam; Brett P Monia; Stanley T Crooke; Rosanne M Crooke Journal: J Lipid Res Date: 2007-01-22 Impact factor: 5.922
Authors: Joel A Simon; Feng Lin; Stephen B Hulley; Patricia J Blanche; David Waters; Stephen Shiboski; Jerome I Rotter; Deborah A Nickerson; Huiying Yang; Mohammed Saad; Ronald M Krauss Journal: Am J Cardiol Date: 2006-01-27 Impact factor: 2.778
Authors: Sérgio D J Pena; Giuliano Di Pietro; Mateus Fuchshuber-Moraes; Julia Pasqualini Genro; Mara H Hutz; Fernanda de Souza Gomes Kehdy; Fabiana Kohlrausch; Luiz Alexandre Viana Magno; Raquel Carvalho Montenegro; Manoel Odorico Moraes; Maria Elisabete Amaral de Moraes; Milene Raiol de Moraes; Elida B Ojopi; Jamila A Perini; Clarice Racciopi; Andrea Kely Campos Ribeiro-Dos-Santos; Fabrício Rios-Santos; Marco A Romano-Silva; Vinicius A Sortica; Guilherme Suarez-Kurtz Journal: PLoS One Date: 2011-02-16 Impact factor: 3.240
Authors: Seungbum Choi; Aleksandra Aljakna; Ujala Srivastava; Blake R Peterson; Bin Deng; Annik Prat; Ron Korstanje Journal: Lipids Health Dis Date: 2013-07-24 Impact factor: 3.876
Authors: Mark H Kuniholm; Hua Liang; Kathryn Anastos; Deborah Gustafson; Seble Kassaye; Marek Nowicki; Beverly E Sha; Emilia J Pawlowski; Stephen J Gange; Bradley E Aouizerat; Tatiana Pushkarsky; Michael I Bukrinsky; Vinayaka R Prasad Journal: AIDS Date: 2017-11-28 Impact factor: 4.632